- Frederic Tissot1,*,
- Samir Agrawal2,
- Livio Pagano3,
- Georgios Petrikkos4,
- Andreas H. Groll5,
- Anna Skiada6,
- Cornelia Lass-Flörl7,
- Thierry Calandra1,
- Claudio Viscoli8 and
- Raoul Herbrecht9
- 1 Infectious Diseases Service, University of Lausanne, Switzerland;
- 2 Division of Haemato-Oncology, St Bartholomew's Hospital; Blizard Institute, London, UK;
- 3 Hematology, Catholic University of Sacred Heart Roma, Italy;
- 4 School of Medicine, European University Cyprus, Engomi, Cyprus;
- 5 Infectious Disease Research Program, University Children Hospital, Munster, Germany;
- 6 1st Department of Medicine, University of Athens, Greece;
- 7 Division of Hygiene and Medical Microbiology, Medical University of Innsbruck, Austria;
- 8 University of Genova (DISSAL), Infectious Disease Division, IRCCS San Martino-IST, Genova, Italy;
- 9 Oncology and Hematology, Hopitaux Universitaires de Strasbourg and Universite' de Strasbourg, France
- ↵* Corresponding author; email:
The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematological malignancies or hematopoietic stem cell transplantation recipients. Meetings are held every two years since 2005 and evidence-based recommendations are elaborated after evaluation of the literature and discussion among specialists of nearly all European countries. In this manuscript, the ECIL group presents the 2015-update of the recommendations for the targeted treatment of invasive candidiasis, aspergillosis and mucormycosis. Current data now allow a very strong recommendation in favor of echinocandins for first line therapy of candidemia irrespective of the underlying predisposing factors. Anidulafungin has been given the same grading as the other echinocandins for hemato-oncological patients. The beneficial role of catheter removal in candidemia is strengthened. Aspergillus guidelines now recommend the use of either voriconazole or isavuconazole for first line treatment of invasive aspergillosis, while first line combination antifungal therapy is not routinely recommended. As only few new data were published since the last ECIL guidelines, no major changes were brought to mucormycosis recommendations.
- Received August 5, 2016.
- Accepted December 20, 2016.
- Copyright © 2016, Ferrata Storti Foundation